IMNN IMUNON, Inc.
IMUNON, Inc. (IMNN) is expected to report earnings on November 10, 2026, before the market open. The consensus earnings estimate is a loss of $0.72 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +2.5% since its last earnings release on August 11, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About IMUNON, Inc.
Imunon Inc. is a fully integrated, clinical stage biotechnology company. It focused on advancing a portfolio of treatments which harness the body's natural mechanisms. The company's lead clinical program includes GEN-1. Imunon Inc., formerly known as Celsion Corporation, is based in LAWRENCEVILLE, N.J.
Sector
Healthcare
Industry
Biotechnology